What is the youngest age to administer ceftriaxone (Ceftriaxone is a generic name, it's a third-generation cephalosporin antibiotic)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Ceftriaxone can be administered to infants as young as 29 days old.

Administration Guidelines

  • According to the American Academy of Pediatrics, ceftriaxone is recommended for infants 29 to 90 days of age without signs of meningitis or severe illness 1.
  • The dosage for ceftriaxone in infants 29 to 60 days old is 50 mg/kg per dose every 24 hours for urinary tract infections or when no focus of infection is identified 1.
  • For infants with bacterial meningitis, ceftriaxone can be administered at a dose of 100 mg/kg per day once daily or divided every 12 hours 1.

Important Considerations

  • The use of ceftriaxone in infants younger than 29 days old is not recommended due to the potential risk of interactions with calcium-containing products 1.
  • It is essential to consult local antibiograms to guide antibiotic choices and ensure appropriate coverage for suspected pathogens 1.
  • Ceftriaxone is a third-generation cephalosporin antibiotic and should be used judiciously to minimize the risk of antibiotic resistance 1.
  • The WHO recommends ceftriaxone as a second-choice antibiotic for sepsis in children, to be used in certain cases 1.

From the FDA Drug Label

Ceftriaxone for injection is contraindicated in premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age). Ceftriaxone for injection is contraindicated in neonates (≤ 28 days) if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium- containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium For the treatment of skin and skin structure infections, the recommended total daily dose is 50 to 75 mg/kg given once a day (or in equally divided doses twice a day). For the treatment of acute bacterial otitis media, a single intramuscular dose of 50 mg/kg (not to exceed 1 gram) is recommended

The youngest age to administer ceftriaxone is more than 28 days for full-term neonates not requiring calcium-containing IV solutions, but the exact age in weeks for premature neonates is postmenstrual age of more than 41 weeks 2 2.

From the Research

Administration of Ceftriaxone in Young Patients

  • The youngest age to administer ceftriaxone can be inferred from several studies, including one from 3 where ceftriaxone was administered to newborn and young infants, with ages ranging from 0 to 106 days.
  • In the study by 3, dose levels were 15 to 23 mg/kg every 12 to 24 hours for 2 to 13.5 days, and the drug was well tolerated, although some side effects were observed.
  • Another study by 4 investigated the population pharmacokinetics of ceftriaxone in infants and suggested regimens of 20 mg/kg of body weight twice daily for infants under 1 year of age.
  • The study by 5 also provided dosing recommendations for ceftriaxone in children with severe acute malnutrition, suggesting 80 mg/kg once daily.

Key Findings

  • Ceftriaxone can be administered to infants as young as a few days old, as seen in the study by 3.
  • The appropriate dosage of ceftriaxone varies by age and weight, with studies by 4 and 5 providing specific recommendations.
  • Ceftriaxone is generally well tolerated in young patients, although side effects can occur, as noted in the study by 3.
  • The pharmacokinetics of ceftriaxone in infants and children have been studied, with findings informing optimal dosing regimens, as seen in the studies by 4 and 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.